Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma

Renal medullary carcinoma (RMC) is a rare and lethal renal cell carcinoma characterized by the loss of tumor suppressor SMARCB1. Molecular profiling studies have suggested that RMC cells may be vulnerable to therapies that generate DNA damage, such as the combination of the nucleoside analog gemcitabine, and topoisomerase inhibitor doxorubicin.We retrospectively analyzed the records of patients with RMC treated with gemcitabine plus doxorubicin...